Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | EEF2K | O00418 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803476 | 1.00 | PTGS2 (0.47) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8991923 | 0.88 | PTGS2 (0.49) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8893437 | 0.88 | PTGS2 (0.49) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8822340 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8822335 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7803503 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7803504 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7803500 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7796847 | 0.85 | PTGS2 (0.48) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL7796849 | 0.85 | PTGS2 (0.48) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | PANETTA JILL (US) | 2001-08-30 | — | — | US | disclosed |
| US-5981523-A | ADMINISTERING THIOMORPHOLINONE COMPOUND TO THE PATIENT SUFFERING FROM MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0779282-A1 | Thiomorpholinone compounds for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | TXNRD3, TXNRD2, CTH | PTGS2 418/4885PTGS1 363/4885CYP1A2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.